Blood, bugs, and motion: What do we really know in regard to total joint arthroplasty?

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 1, 2011, Pages 73-80

  Glassner, Philip J ^a   Slover, James D ^b   Bosco III, Joseph A ^c   Zuckerman, Joseph D ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b Division of Adult Reconstructive Surgery

^c Department of Orthopaedic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IRON;

ARTHROPLASTY; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; COST BENEFIT ANALYSIS; HUMAN; KNEE ARTHROPLASTY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PASSIVE MOVEMENT; POSTOPERATIVE INFECTION; PREOPERATIVE EVALUATION; TOTAL JOINT ARTHROPLASTY;

ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD DONORS; ERYTHROPOIETIN; HUMANS; KNEE JOINT; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MOTION THERAPY, CONTINUOUS PASSIVE; RANGE OF MOTION, ARTICULAR;

EID: 79952013215     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Keating EM. Hemoglobin management in hip arthroplasty. Semin Arthroplasty. 2000;11:174.
2. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion. 1992;32:601-606.
3. Keating EM, Ritter MA. Transfusion options in total joint arthroplasty. J Arthroplasty 2002;17(4 Suppl. 1):125-128.
4. Keating EM, Callaghan JJ, Ranawat AS, et al. A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. J Arthroplasty. 2007 Apr;22(3):325-333.
5. Bern MM, Bierbaum BE, Katz JN, Losina E. Autologous blood donation and subsequent blood use in patients undergoing total knee arthroplasty. Transfus Med. 2006;16:313-319.
6. Hatzidakis AM, Mendlick RM, McKillip T, et al. Preoperative autologous donation for total joint arthroplasty. An analysis of risk factors for allogenic transfusion. J Bone Joint Surg Am. 2000 Jan;82(1):89-100.
7. Martinez V, Monsaingeon-Lion A, et al. Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. Br J Anaesth. 2007;99:794-800.
8. Stulberg B, Zadzilka J. Blood management issues using blood management strategies. J Arthroplasty. 2007 Jun;22(4 Suppl 1):95-98.
9. Stulberg BN, Thomas J. Blood Conservation in Hip Surgery. In: Callaghan JJ, Rosenberg AG, Rubash HE (eds). The Adult Hip, Vol 1 (2nd ed). Philadelphia: Lippincott Williams & Wilkins, 2007, p. 643.
10. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993;6:428-442.
11. Boyce JM, Potter-Bynoe G, Dziobek L. Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery. Infect Control Hosp Epidemiol. 1990;11:89-93.
12. Green JW, Wenzel RP. Postoperative wound infection: a controlled study of the increased duration of hospital stay and direct cost of hospitalization. Ann Surg. 1977;185:264-268.
13. Nelson RM, Dries DJ. The economic implications of infection in cardiac surgery. Ann Thorac Surg. 1986;42:240-246.
14. Kirkland KB, Briggs JP, et al. The impact of surgical-site infections in the 1990s: Attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999;20:725-730.
15. Shams W, Rapp R. Methicillin-resistant staphylococcal infections: an important consideration for orthopedic surgeons. Orthopedics. 2004; 27(6): 565-568.
16. Rezende NA, Blumberg HM, Metzger BS, et al. Risk factors for methicillin-resistance among patients with Staphylococcus aureus bacteremia at the time of hospital admission. Am J Med Sci. 2002;323:117-123.
17. Wyllie DH, Peto TE, Crook D. MRSA bacteraemia in patients on arrival in hospital: a cohort study in Oxfordshire 1997-2003. BMJ. 2005;331:992.
18. O'Sullivan NP, Keane CT. Risk factors for colonization with methicillin-resistant Staphylococcus aureus among nursing home residents. J Hosp Infect. 2000;45:206-210.
19. Maudsley J, Stone SP, Kibbler CC, et al. The community prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in older people living in their own homes: Implications for treatment, screening and surveillance in the UK. J Hosp Infect. 2004; 57:258-262.
20. Trick WE, Weinstein RA, DeMarais PL, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc 2001;49:270-276.
21. Hassan K, Paturi A, et al. The prevalence of methicillin resistant Staphylococcus aureus in orthopaedics in a non-selective screening policy. Surgeon. 2008;1:201-203.
22. Wilcox MH, Hall J, et al. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J Hosp Infect. 2003;54:196-201.
23. Nixon M, Jackson B, et al. Methicillin-resistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control. J Bone Joint Surg Br. 2006;88:812-817.
24. Sankar B, Hopgood P, Bell KM. The role of MRSA screening in joint-replacement surgery. Int Orthop. 2005;29:160-163.
25. Jog S, Cunningham R, et al. Impact of preoperative screening for methicillin-resistant Staphylococcus aureus by real-time polymerase chain reaction in patients undergoing cardiac surgery. J Hosp Infect. 2008;69:124-130.
26. Perl T, Cullen J, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002; 346:1871-1877.
27. Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2006;27(12):1304-1312.
28. Salter RB, Simmonds DF, et al. The biological effect of continuous passive motion on the healing of full-thickness defects in articular cartilage: an experimental investigation in the rabbit. J Bone Joint Surg Am. 1980;62(8):1232-1251.
29. Salter RB, Hamilton HW, et al. Clinical application of basic research on continuous passive motion for disorders and injuries of synovial joints: a preliminary report of a feasibility study. J Orthop Res. 1984;1(3):325-342.
30. Salter RB. The biologic concept of continuous passive motion of synovial joints. The first 18 years of basic research and its clinical application. Clin Orthop Relat Res. 1989;12-25.
31. Coutts RD, Toth C, Kaita JH. The role of continuous passive motion in the rehabilitation of the total knee patient. In: DS HU (ed): TKA: A Comprehensive Approach. Baltimore: Williams & Wilkins, 1984, pp. 126-132.
32. Milne S, Brosseau L, Robinson V, et al. Continuous passive motion following total knee arthroplasty. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD004260.
33. Lenssen TA, van Steyn MJ, Crijns YH, et al. Effectiveness of prolonged use of continuous passive motion (CPM), as an adjunct to physiotherapy, after total knee arthroplasty. BMC Musculoskelet Disord. 2008 Apr 29;9:60.
34. Bennett LA, Brearley SC, Hart JA, Bailey MJ. A comparison of 2 continuous passive motion protocols after total knee arthroplasty. J Arthroplasty. 2005;20(2):225-233.
35. Colwell CW, Morris BA. The influence of continuous passive motion on the results of total knee arthroplasty. Clin Orthop Relat Res. 1992;276:225.
36. Denis M, Moffet H, Caron F, et al. Effectiveness of continuous passive motion and conventional physical therapy after total knee arthroplasty: a randomized clinical trial. Phys Ther. 2006 Feb;86(2):174-185.